By admin 
The central conflict revolves around Enbrel, Amgen’s blockbuster treatment for rheumatoid arthritis and psoriasis, which has generated tens of billions of dollars in revenue since its initial approval in 1998. Humana alleges that Amgen engaged in a sophisticated scheme to extend its monopoly on Enbrel far beyond the expiration of its original patents. According to the complaint, Amgen’s strategy involved the acquisition of "submarine patents"—applications that linger in the patent office for years before emerging to catch competitors off guard—and the strategic purchase of patent rights from third parties that could have otherwise been used to challenge Amgen’s dominance. By absorbing these external intellectual property assets, Humana argues, Amgen effectively "crowded out" the possibility of biosimilar entry, forcing insurers and patients to pay premium prices for a drug that, by traditional standards, should have faced low-cost competition years ago.
The significance of this case has been amplified by the unexpected and forceful intervention of the Federal Trade Commission (FTC). Under the leadership of Chair Lina Khan, the FTC has adopted an aggressive stance toward what it characterizes as "pharmaceutical gamesmanship." In a recent amicus brief filed in the litigation, the FTC argued that the acquisition of patent rights falls squarely under the jurisdiction of Section 7 of the Clayton Act, a century-old law typically used to block anticompetitive corporate mergers. The FTC’s position is that a patent is an asset, and the acquisition of an asset that significantly lessens competition or tends to create a monopoly is a violation of federal law. This interpretation marks a pivot in antitrust enforcement, suggesting that the government is no longer content to merely police how companies use their own inventions, but will now scrutinize how they buy the inventions of others to shore up their market power.
To understand the weight of this legal challenge, one must look at the broader context of "patent thickets" and "evergreening" in the pharmaceutical industry. A patent thicket refers to a dense web of overlapping intellectual property rights that a company builds around a single product. For Enbrel, Amgen has successfully defended a fortress of patents that could potentially keep biosimilars off the market until 2029—more than 30 years after the drug first launched. This strategy is not unique to Amgen. AbbVie’s Humira, once the world’s best-selling drug, was famously protected by over 130 patents, a tactic that delayed competition for years and cost the U.S. healthcare system billions. However, the Humana v. Amgen case introduces a specific wrinkle: the role of acquired patents. If a company can simply buy up any emerging patent application that might offer a "work-around" for a competitor, the incentive for rivals to innovate or challenge existing patents is severely diminished.
Legal experts suggest that the outcome of this case could redefine the "Rule of Reason" analysis used in antitrust law. Traditionally, courts have been hesitant to interfere with patent rights, viewing the temporary monopoly granted by the U.S. Patent and Trademark Office as a necessary incentive for the high-risk, high-cost world of drug development. Amgen’s defense rests largely on this foundation, arguing that its patents were legally obtained and that it is merely exercising its right to exclude others, as granted by the Constitution. Amgen maintains that the patents in question cover legitimate technological improvements and that the acquisition of rights from other entities is a standard business practice that facilitates further research and development. From the industry’s perspective, a ruling in favor of Humana and the FTC could cast a "chilling effect" on licensing deals and collaborations, which are often the lifeblood of biotech innovation.
However, the economic data supporting the plaintiffs’ concerns is staggering. According to reports from the Initiative for Medicines, Access, and Knowledge (I-MAK), the top 12 best-selling drugs in the U.S. are protected by an average of 125 patent applications each. These "thickets" provide an average of 38 years of intended patent life, nearly double the 20-year term intended by Congress. For patients, this translates directly to the pharmacy counter. When competition is delayed, prices remain high. In the case of etanercept (Enbrel), the lack of biosimilar competition in the U.S. stands in stark contrast to the European market, where multiple biosimilars have been available for years, leading to price reductions of 50% or more. The FTC argues that by acquiring "blocking" patents, Amgen didn’t just compete; it effectively purchased the right to prevent competition, a move that the commission claims has no pro-competitive justification.
The case also touches upon the "patent dance" established by the Biologics Price Competition and Innovation Act (BPCIA). This framework was intended to create a streamlined path for biosimilars, but critics argue it has been co-opted by large manufacturers to smoke out potential rivals and bury them in litigation. By acquiring third-party patents, a manufacturer can add new layers to this "dance," forcing a biosimilar applicant to litigate not only against the manufacturer’s own patents but also against a rotating cast of acquired intellectual property. This creates a "war of attrition" that small-scale biosimilar developers simply cannot afford to win.
As the litigation progresses in the federal courts, the pharmaceutical industry is watching with bated breath. A victory for Humana would provide a potent new roadmap for other insurers and healthcare payers to sue drugmakers for billions in "overcharge" damages. It would also signal to the SEC and the Department of Justice that pharmaceutical M&A activity involving intellectual property portfolios will face much tougher scrutiny. On the other hand, a victory for Amgen would solidify the current "patent fortress" model, affirming that as long as a patent is validly issued, the method by which a company acquires it—and the intent behind that acquisition—is largely irrelevant to antitrust law.
The political climate adds another layer of complexity. Both the Biden administration and various members of Congress have expressed growing frustration with drug prices. The Inflation Reduction Act (IRA) has already begun to tackle pricing through Medicare negotiations, but those provisions do not address the underlying patent strategies that prevent competition in the private market. The Humana case represents a private-sector attempt to use the judiciary to achieve what the legislature has so far found difficult: a dismantling of the structural barriers to generic entry.
In its amicus brief, the FTC was careful to note that it does not believe all patent acquisitions are illegal. Rather, the agency is targeting acquisitions that are "likely to facilitate the maintenance of a monopoly." This distinction is crucial. It suggests that in the future, the "intent" and "market effect" of a patent purchase will be scrutinized. If a company buys a patent to integrate a new technology into its pipeline, it may be safe. If it buys a patent solely to prevent a competitor from using it as a "freedom to operate" shield, it could face a massive antitrust lawsuit.
The stakes for Amgen are particularly high. Enbrel remains a cornerstone of its portfolio, and any ruling that invalidates its patent strategy or opens the door to massive damages from insurers like Humana could significantly impact its valuation and future R&D spending. For Humana, the case is a stand against the rising costs of specialty drugs, which represent an ever-increasing share of its payout obligations. As both sides prepare for the next round of oral arguments, the legal community is bracing for a decision that will either reinforce the sanctity of the patent system or usher in a new era of antitrust accountability for Big Pharma.
Ultimately, the resolution of this battle will likely hinge on how the court balances the "exclusionary power" of a patent with the "anticompetitive intent" of the patent holder. If the court agrees with the FTC that patents are assets subject to Section 7 of the Clayton Act, it will mark the most significant shift in pharmaceutical antitrust enforcement in a generation. Such a ruling would effectively put an end to the era of "buying the competition" through intellectual property acquisitions, potentially clearing the way for a more robust and timely entry of affordable biosimilars into the American healthcare market. For now, the industry remains in a state of high-stakes suspense, waiting to see if the "patent thicket" will finally be pruned by the shears of antitrust law.
